Agile Therapeutics, Inc.
AGRX
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -1,024.77% | 128.72% | -460.15% | 79.04% | 29.37% |
| Total Depreciation and Amortization | -0.97% | 3.00% | 2.04% | 3.16% | 2.15% |
| Total Amortization of Deferred Charges | -100.00% | -40.00% | -10.71% | -9.68% | -9.12% |
| Total Other Non-Cash Items | 343.90% | -359.04% | 148.35% | -159.01% | -0.34% |
| Change in Net Operating Assets | 2,104.69% | -104.53% | -27.67% | 200.26% | -184.93% |
| Cash from Operations | 109.41% | -1,539.53% | -52.88% | 104.28% | -434.11% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -277.25% | -40.23% | -21.68% | -27.11% |
| Issuance of Common Stock | -100.00% | 437,500.00% | -98.57% | -99.02% | 613.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 620.53% | -75.18% | -104.04% | 783.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -200.00% | -- | -- |
| Net Change in Cash | 294.92% | 118.67% | -459.09% | 105.35% | -101.22% |
